60Degrees_logo_RGB_Logo.jpg
60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment
July 09, 2024 06:31 ET | Sixty Degrees Pharmaceuticals
60 Degrees Pharma wins IRB approval for tafenoquine study for treating persistent babesiosis in immunocompromised patients despite prior treatment.
ZyversaREV_cmyk.jpg
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
March 18, 2024 07:57 ET | ZyVersa Therapeutics
Initiation of Phase 2a trial first half 2024 with Cholesterol Efflux Mediator VAR 200 in diabetic kidney disease is a key milestone for ZyVersa.
lexingtonbiologo.jpg
Lexington Receives Approval to Commence Clinical Study
January 24, 2018 09:00 ET | Lexington Biosciences, Inc.
VANCOUVER, British Columbia, Jan. 24, 2018 (GLOBE NEWSWIRE) -- Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is...